THE QUIET MOVER

A SHARP FOCUS ON BIOSIMILARS HAS PROPELLED LOW-PROFILE AUROBINDO PHARMA TO SECOND PLACE IN THE INDIAN PHARMA PECKING ORDER, WHERE IT HAS STAYED DESPITE THE PANDEMIC. THE JOURNEY TO NO. 1, THOUGH, WILL BE TOUGHER

BY NEETU CHANDRA SHARMA

NOWHERE IS INDIA’S EPITHET—pharmacy of the world—more apt than in the case of some big pharmaceutical companies. One such company is Aurobindo Pharma, which has steadily grown over the past 10 years to become the second-biggest Indian pharma company behind only Sun Pharma. Its consolidated revenues grew from ₹4,550.56 crore in FY12 to ₹23,366.55 crore in FY22. Ten years ago, it was placed sixth (see table ‘Coming from Behind’). So, how did the Hyderabad-headquartered company reach such stratified air? Aurobindo has adopted a strategy of focussing on its forte of biosimilars (medicines that are highly similar to their branded reference medicines) along with gradually advancing in speciality pharmaceuticals (large, injectable, protein-based molecules, or small molecules used to treat complex conditions such as cancer and hepatitis C or common chronic diseases such…

You're reading a preview of

Business Today (Digital) - 1 Issue, 18 September 2022

DiscountMags is a licensed distributor (not a publisher) of the above content and Publication through Zinio LLC. Accordingly, we have no editorial control over the Publications. Any opinions, advice, statements, services, offers or other information or content expressed or made available by third parties, including those made in Publications offered on our website, are those of the respective author(s) or publisher(s) and not of DiscountMags. DiscountMags does not guarantee the accuracy, completeness, truthfulness, or usefulness of all or any portion of any publication or any services or offers made by third parties, nor will we be liable for any loss or damage caused by your reliance on information contained in any Publication, or your use of services offered, or your acceptance of any offers made through the Service or the Publications. For content removal requests, please contact Zinio.